Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Storer

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Journal of Biological Response Modifiers|April 1, 1988
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2N S Rosenthal, J A Hank, P C Kohler, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Research|April 1, 1988
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2J A Hank, P C Kohler, G Weil-Hillman, et al.
Cancer Research|March 15, 1993
A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humansJ H Schiller, J Hank, B Storer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1996
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcomaG J Wiedemann, H I Robins, S Gutsche, et al.
Bone Marrow Transplantation|November 24, 2004
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioningM E D Flowers, F Traina, B Storer, et al.
Leukemia|November 5, 2005
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysisB L Scott, B M Sandmaier, B Storer, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Journal of Biological Response Modifiers|April 1, 1988
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2N S Rosenthal, J A Hank, P C Kohler, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Research|April 1, 1988
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2J A Hank, P C Kohler, G Weil-Hillman, et al.
Cancer Research|March 15, 1993
A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humansJ H Schiller, J Hank, B Storer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1996
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcomaG J Wiedemann, H I Robins, S Gutsche, et al.
Bone Marrow Transplantation|November 24, 2004
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioningM E D Flowers, F Traina, B Storer, et al.
Leukemia|November 5, 2005
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysisB L Scott, B M Sandmaier, B Storer, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patientsM R Albertini, J A Hank, J H Schiller, et al.
Pageof 13